The Tufts Daily

Dissertation Diaries: Nicholas Mandel

Welcome back to a new semester of Dissertation Diaries. As a reminder, this is the series where we highlight Ph.D. students ...
Science Daily

A “dormant” brain protein turns out to be a powerful switch

Scientists at Johns Hopkins have uncovered a surprising new way to influence brain activity by targeting a long-mysterious class of proteins linked to anxiety, schizophrenia, and movement disorders.
Technology Networks

GluD Receptors Emerge as a Tunable Target for Neuropsychiatric Disorders

Johns Hopkins researchers found that delta-type ionotropic glutamate receptors (GluDs) play a key role in regulating neuronal ...
Asianet Newsable on MSN

Hidden brain protein found to control how brain cells communicate

Scientists reveal the GluD brain protein's active role, offering new hope for mental health. Discover how this breakthrough ...
Belfast News Letter on MSN

Vital regional neuromuscular service offers lifeline to patients at Thompson House Hospital

​A “busy person” all his life, 73-year-old Gerard ‘Gerry’ Heaney from Craigavon was diagnosed in 2018 with the rare and ...

NHS issues urgent advice for anyone taking clonazepam

The NHS has important information for anyone who has been prescribed clonazepam - a common medication used to treat a variety of conditions ...
Fierce Pharma

IntraBio's Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win

As IntraBio works to grow the global treatment market for Aqneursa in Niemann-Pick disease type C, the company is already ...
The Manila Times

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company” or "Solid”), a life sciences company developing precision genetic ...

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

About the FALCON Trial FALCON is a first-in-human, open-label, multi-center Phase 1b clinical trial designed to evaluate the safety and tolerability of SGT-212 in participants aged 18-40 who have been ...

NHS urgent warning to anyone prescribed medication for restless legs syndrome

Your doctor may give you a prescription, but it comes with a warning ...
Labroots

A Novel Mouse Model of Ataxia Telangiectasia for Testing Small Molecule Readthrough (SMRT) Compounds

Investigator & Co-Director of the Neurotherapeutics IWI, Lundquist Institute (Formerly "LA BioMed"); Assistant Professor, David Geffen School of Medicine at UCLA Department of Neurology Ataxia ...

Solid Biosciences Inc.: Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular ...